Cyclacel Pharmaceuticals, Inc. (CYCCP) Stock Price, Financial Report, & Fundamental Analysis
NASDAQ:CYCCPCyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.
(0.9)
Cyclacel Pharmaceuticals, Inc. Fundamental Analysis
Strength
| Analysis | # |
|---|---|
Price to Book (PBV) RatioUndervalued price-to-book. CYCCP stock price is under 1x the price-to-book value. |
|
Debt-Equity Ratio (DER)CYCCP equity is higher than it's debt. |
|
Dividend YieldCYCCP has high dividend yield (5.97%). |
Weakness
| Analysis | # |
|---|---|
Market CapSmall market capitalization. Market capitalization is less than 2bn USD |
|
Revenue GrowthCYCCP has never had growing revenue. |
|
Net Income GrowthCYCCP has never had growing net income. |
|
Net IncomeCYCCP never has positive net income for 2 years. |
|
Return of AssetsCYCCP has low return of asset (-46.75%). |
|
Return of EquityCYCCP has low return of equity (-59.65%). |
|
RevenueCYCCP never has positive revenue for 2 years. |
|
Return of Invested CapitalCYCCP has low ROIC. |
Competitors
Cyclacel Pharmaceuticals, Inc. Financials
Financial statements are written records that convey the business activities and the financial performance of a company. Financial statements include the balance sheet, income statement, and statement of cash flow.
Income Statement
Also known as the profit and loss (P&L) statement or the statement of revenue and expense, the income statement primarily focuses on the company’s revenue and expenses during a particular period.
- Revenue
- 0 USD
- Cost
- 0 USD
- Net Income
- -18,887,000 USD
- Profit Margin
- 0%
Cashflow Statement
A cash flow statement is a financial statement that provides aggregate data regarding all cash inflows a company receives from its ongoing operations and external investment sources. It also includes all cash outflows that pay for business activities and investments during a given period.
- Free Cash Flow
- -18,567,000 USD
Balance Sheet
Liquidity & Solvency
Solvency refers to an company's capacity to meet its long-term financial commitments. Liquidity refers to an company's ability to pay short-term obligations. The term also refers to a company's capability to sell assets quickly to raise cash.
Short Term Liabilities
| Quick Ratio | 637.38% |
Long Term Liabilities
| Liquidity/Current Ratio | 641.28% |
Dividend
| Dividend Yield | 5.97% |
| Dividend Payout Ratio (DPR) | -7.87% |
| Dividend Payout Ratio (DPR) | -7.87% |
| Dividend per Share | 0,60 USD |
Financial Ratios
| Price to Earning (PER) | -4.9x |
| Price to Earning-Growth (PEG) | 0x |
| Price to Book Value (PBV) | -7.87x |
| Liquidity/Current Ratio | 641.28% |
| Cash Ratio | 544.59% |
| Debt Ratio | 14.38% |
| Debt-Equity Ratio (DER) | 16.79% |
| Net Profit Margin (NPM) | 0% |
| Return of Assets (ROA) | -46.75% |
| Return of Equity (ROE) | -59.65% |
| Return on Capital Employed (ROCE) | -73.35% |
| Days of Sales Outstanding (DSO) | 0 |
| Days of Inventory Outstanding (DIO) | 0 |
| Days Payable Outstanding (DPO) | 0 |
| Operating Cycle (OC) | 0 |
| Cash Conversion Cycle (CCC) | 0 |
Cyclacel Pharmaceuticals, Inc. Executives
CEO
- CEO Name
- Mr. Spiro George Rombotis
Management
Cyclacel Pharmaceuticals, Inc. Profile
About Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.
Additional Information
- Company name
- Cyclacel Pharmaceuticals, Inc.
- Symbol
- NASDAQ:CYCCP
- Exchange
- NASDAQ Capital Market
- Industry
- Biotechnology
- Sector
- Healthcare
- Address
-
200 Connell Drive
Berkeley Heights
NJ
US
07922 - Website
- https://www.cyclacel.com